# ADJUVANT (NCT01405079)

> Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01405079
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Guangdong Association of Clinical Trials
- Conditions: Non-small Cell Lung Cancer
- Interventions: Gefitinib; Vinorelbine+Cisplatin
- Enrollment: 222
- Primary outcome: Disease free survival

## Indexed commentary on ADJUVANT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 21 posts on X
- 3 podcast episodes
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=adjuvant-nct01405079

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01405079", "email": "<work email>"}; the inbox owner confirms by the emailed link.